Monographie - Bortezomib

Son güncelleme :
03/05/2024

Bortezomib

Kimyasal yapı

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Bemoncaz	Meksika
Bicavan	Şili
Biemib	Türkiye
Bomib	Meksika
Borater	Arjantin
Borcade	Türkiye
Bormib	Arjantin
Bortezomib	Yeni Zelanda
Bortezun	Ekvador
Bortrac	Ekvador, Peru
Bortzo	Peru
Botemib	Ekvador, Peru, Şili
Bozix	Peru, Şili
Bozob	Arjantin, Ekvador, Peru
Bromadene	Arjantin
Egybort	Hindistan
Elomaziv	Meksika
Gysatri	Arjantin
Miasoma	Arjantin
Mibor	Peru
Multizom	Arjantin
Rebtik	Şili
Velcade	Almanya, Amerika Birleşik Devletleri, Arjantin, Avustralya, Avusturya, Belçika, Birleşik Arap Emirlikleri, Büyük Britanya, Danimarka, Finlandiya, Fransa, Hollanda, İrlanda, İspanya, İsveç, İsviçre, İtalya, İzlanda, Japonya, Kanada, Kolombiya, Lüksemburg, Macaristan, Malezya, Meksika, Mısır, Norveç, Polonya, Portekiz, Romanya, Şili, Suudi Arabistan, Türkiye, Venezuela, Yeni Zelanda, Yunanistan
Velcord	Peru
Vortemyel	Romanya
Zefra	Arjantin
Zegomib	Romanya
Zuricade	Meksika

Kaynaklar : Bortezomib

	Tip	Yayın
1911	Laboratuar	Bortezomib (Velcade®) - Summary of Product Characteristics Janssen-Cilag Ltd 2016
2010	Dergi	André P, Cisternino S, Chiadmi F, Toledano A, Schlatter J, Fain O, Fontan JE. Stability of bortezomib 1 mg/ml solution in plastic syringe and glass vial. Ann Pharmacotherapy 2005 ; 39: 1462-1466.
2011	Dergi	Friess D, Nguyen HC, Lipp HP. HPLC-stabilitätuntersuchungen zu rekonstituierten Bortezomib-Lösungen. Krankenhauspharmazie 2005 ; 26, 6: 206-210.
2232	Dergi	Walker SE, Milliken D, Law S. Stability of Bortezomib Reconstituted with 0.9% Sodium Chloride at 4°C and Room Temperature (23°C) Can J Hosp Pharm 2008 ; 61, 1: 14-20.
3190	Dergi	Bolognese A, Esposito A, Manfra M, Catalano L, Petruzziello F, Martorelli MC, Pagliuca R, Mazzarelli V, Ottiero M, Scalfaro M, An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. Advance in Haematology 2009 Article ID 704928, 5 page
3240	Afiş	Perissutti M, Vigneron J, Zenier H, May I, Demoré B. Etude de la stabilité d'une solution de bortézomib à 1 mg/mL conditionnée en seringue de polypropylène. Congrès SFPO 2011
3337	Dergi	Carati D, Masini C, Minguzzi M, Petocchi B, Romanazzi C, Rondoni C, Sangiorgi E, Sferra S, Simonetta S, Stancari A, Locchi F, Z Stability of bortezomib reconstituted under clinical use conditions in original vials and polypropylene syringes at 4 °C and room temperature. EJHP 2012 ; 19: 428-431.
3349	Dergi	Bosch-Ojeda C, Sanchez-Rojas M.F, Espinosa-Bosch M. Chemical stability of bortezomib solutions in original manufacturer vials. Int J Pharm Bio Sci 2012 ; 2, 3: 344-350.
3418	Dergi	Berruezo garcia J, Espinosa Bosch M, Sanchez Rojas F, Bosch Ojeda C Chemical stability of bortezomib solutions in original manufacturer vial at room temperature and in syringe at 4°C. Int J Pharm Bio Sci 2013 ; 3, 1: 449-458.
3447	Afiş	Giovanelli M, Vigneron J, May I, Nicolas A. Etude de la stabilité d’une solution de bortézomib à 2,5 mg/mL par chromatographie liquide à haute performance couplée à un détecteur à barrettes de diodes et à un détecteur évaporatif à diffusion de lumière. SFPO Congress, Mandelieu, France 2013
3537	Dergi	Lipp HP, Gfrörer W, Riedmüller S. Bortezomib zur subkutanen Applikation. Krankenhauspharmazie 2013 ; 34,11: 500-505.
3688	Dergi	Walker S.E, Charbonneau L.F, Law S. Stability of bortezomib 2.5 mg/mL in vials and syringes stored at 4°C and room temperature (23°C). Can J Hosp Pharm 2014 ; 67, 2: 102-107
4137	Dergi	Patel T, Sewell G. Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare). Newsletter Stabilis 2018 41;2-6
4485	Dergi	Law S, Charbonneau L, Iazetta J, Perks W, Ma N, Walker S.E. Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored 4°C and Room Temperature (23°C) Can J Hosp Pharm 2021 ;74;1:57-69

Mentions Légales